A novel p53/microRNA-22/Cyr61 axis in synovial cells regulates inflammation in rheumatoid arthritis

Arthritis and Rheumatology

Volumn 66, Issue 1, 2014, Pages 49-59

  Lin, Jinpiao ^a   Huo, Rongfen ^a   Xiao, Lianbo ^b   Zhu, Xianjin ^a   Xie, Jun ^b   Sun, Songtao ^b   He, Yong ^b   Zhang, Jie ^a   Sun, Yue ^a   Zhou, Zhou ^a   Wu, Pinru ^a   Shen, Baihua ^a   Li, Dangsheng ^c   Li, Ningli ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Guanghua Rheumatology Hospital   (China)

^c Chinese Academy of Sciences   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE RICH PROTEIN 61; INTERLEUKIN 6; MESSENGER RNA; MICRORNA 22; PROTEIN KINASE B; PROTEIN P53; CYR61 PROTEIN, HUMAN; CYTOKINE; MICRORNA; MIRN22 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA SEQUENCE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; INFLAMMATION; LUCIFERASE ASSAY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SOMATIC MUTATION; SYNOVIOCYTE; SYNOVIUM; WESTERN BLOTTING; AGED; CELL LINE; CELL STRAIN HCT116; FIBROBLAST; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

3' UNTRANSLATED REGIONS; ADULT; AGED; ARTHRITIS, RHEUMATOID; CELL LINE; CYSTEINE-RICH PROTEIN 61; CYTOKINES; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; HCT116 CELLS; HELA CELLS; HUMANS; MALE; MICRORNAS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84897019409     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38142     Document Type: Article

References (50)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61. (Pubitemid 40852711)
2. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors? [review]. Arthritis Rheum 1996;39:1781-90. (Pubitemid 26378569)
3. Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol 2013;9:24-33.
4. Zhang Q, Wu J, Cao Q, Xiao L, Wang L, He D, et al. A critical role of Cyr61 in interleukin-17-dependent proliferation of fibroblastlike synoviocytes in rheumatoid arthritis. Arthritis Rheum 2009;60:3602-12.
5. Lin J, Zhou Z, Huo R, Xiao L, Ouyang G, Wang L, et al. Cyr61 induces IL-6 production by fibroblast-like synoviocytes promoting Th17 differentiation in rheumatoid arthritis. J Immunol 2012;188:5776-84.
6. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31. (Pubitemid 27131374)
7. Firestein GS, Nguyen K, Aupperle KR, Yeo M, Boyle DL, Zvaifler NJ. Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol 1996;149:2143-51. (Pubitemid 26415230)
8. Kullmann F, Judex M, Neudecker I, Lechner S, Justen HP, Green DR, et al. Analysis of the p53 tumor suppressor gene in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 1999;42:1594-600. (Pubitemid 30263625)
9. Inazuka M, Tahira T, Horiuchi T, Harashima S, Sawabe T, Kondo M, et al. Analysis of p53 tumour suppressor gene somatic mutations in rheumatoid arthritis synovium. Rheumatology (Oxford) 2000;39:262-6. (Pubitemid 30204209)
10. Han Z, Boyle DL, Shi Y, Green DR, Firestein GS. Dominantnegative p53 mutations in rheumatoid arthritis. Arthritis Rheum 1999;42:1088-92. (Pubitemid 29268944)
11. Aupperle KR, Boyle DL, Hendrix M, Seftor EA, Zvaifler NJ, Barbosa M, et al. Regulation of synoviocyte proliferation, apoptosis, and invasion by the p53 tumor suppressor gene. Am J Pathol 1998;152:1091-8. (Pubitemid 28173371)
12. Pap T, Aupperle KR, Gay S, Firestein GS, Gay RE. Invasiveness of synovial fibroblasts is regulated by p53 in the SCID mouse in vivo model of cartilage invasion. Arthritis Rheum 2001;44:676-81. (Pubitemid 32234627)
13. Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A 2002;99:10025-30. (Pubitemid 34831166)
14. Weaver RF. Section 5: posttranslational events. In: Molecular biology. 4th ed. Boston: McGraw Hill Higher Education; 2007. p. 394-471.
15. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33.
16. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009;136:642-55.
17. Ceribelli A, Yao B, Dominguez-Gutierrez PR, Nahid MA, Satoh M, Chan EK. MicroRNAs in systemic rheumatic diseases. Arthritis Res Ther 2011;13:229.
18. Ceribelli A, Nahid MA, Satoh M, Chan EK. MicroRNAs in rheumatoid arthritis. FEBS Lett 2011;585:3667-74.
19. Zhang Y, Diao Z, Su L, Sun H, Li R, Cui H, et al. MicroRNA-155 contributes to preeclampsia by down-regulating CYR61. Am J Obstet Gynecol 2010;202:466.e1-7.
20. Donate PB, Fornari TA, Macedo C, Cunha TM, Nascimento DC, Sakamoto-Hojo ET, et al. T cell post-transcriptional miRNAmRNA interaction networks identify targets associated with susceptibility/resistance to collagen-induced arthritis. PLoS One 2013;8:e54803.
21. Xiong J. Emerging roles of microRNA-22 in human disease and normal physiology. Curr Mol Med 2012;12:247-58.
22. Pandey DP, Picard D. miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor α mRNA [published erratum appears in Mol Cell Biol 2009;29:4873]. Mol Cell Biol 2009;29:3783-90.
23. Ling B, Wang GX, Long G, Qiu JH, Hu ZL. Tumor suppressor miR-22 suppresses lung cancer cell progression through posttranscriptional regulation of ErbB3. J Cancer Res Clin Oncol 2012;138:1355-61.
24. Jiang R, Deng L, Zhao L, Li X, Zhang F, Xia Y, et al. miR-22 promotes HBV-related hepatocellular carcinoma development in males. Clin Cancer Res 2011;17:5593-603.
25. Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, et al. miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol 2011;193:409-24.
26. Feng Z, Zhang C, Wu R, Hu W. Tumor suppressor p53 meets microRNAs. J Mol Cell Biol 2011;3:44-50.
27. Tsuchiya N, Izumiya M, Ogata-Kawata H, Okamoto K, Fujiwara Y, Nakai M, et al. Tumor suppressor miR-22 determines p53-dependent cellular fate through post-transcriptional regulation of p21. Cancer Res 2011;71:4628-39.
28. Sun Y, Cheung HS. p53, proto-oncogene and rheumatoid arthritis. Semin Arthritis Rheum 2002;31:299-310. (Pubitemid 34415255)
29. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
30. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
31. Menendez JA, Mehmi I, Griggs DW, Lupu R. The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr Relat Cancer 2003;10:141-52. (Pubitemid 36758643)
32. Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A 1997;94:10895-900. (Pubitemid 27430832)
33. Reme T, Travaglio A, Gueydon E, Adla L, Jorgensen C, Sany J. Mutations of the p53 tumour suppressor gene in erosive rheumatoid synovial tissue. Clin Exp Immunol 1998;111:353-8. (Pubitemid 28088317)
34. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclindependent kinases. Cell 1993;75:805-16. (Pubitemid 23346377)
35. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19. (Pubitemid 23259742)
36. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. The p53 network. J Biol Chem 1998;273:1-4. (Pubitemid 28042164)
37. Kireeva ML, Mo FE, Yang GP, Lau LF. Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol Cell Biol 1996;16:1326-34. (Pubitemid 26095602)
38. Jun. JI, Lau LF. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov 2011;10:945-63.
39. Lau LF. CCN1/CYR61: the very model of a modern matricellular protein. Cell Mol Life Sci 2011;68:3149-63.
40. Cogen PH, McDonald JD. Tumor suppressor genes and medulloblastoma. J Neurooncol 1996;29:103-12. (Pubitemid 26193509)
41. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004. (Pubitemid 38327724)
42. Wales MM, Biel MA, El Deiry W, Nelkin BD, Issa JP, Cavenee WK, et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med 1995;1:570-7.
43. Schultz DC, Vanderveer L, Berman DB, Hamilton TC, Wong AJ, Godwin AK. Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res 1996;56:1997-2002. (Pubitemid 26119896)
44. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009;9:749-58.
45. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996;10:1054-72. (Pubitemid 26152848)
46. Lee YH, Bae SC, Choi SJ, Ji JD, Song GG. Associations between the p53 codon 72 polymorphisms and susceptibility to systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis. Lupus 2012;21:430-7.
47. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004;108:196-9. (Pubitemid 37541770)
48. Houssiau FA, Devogelaer JP, Van Damme J, De Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988;31:784-8.
49. Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 1997;40:1096-105. (Pubitemid 27242297)
50. Santhanam U, Ray A, Sehgal PB. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A 1991;88:7605-9. (Pubitemid 21915202)